![Explainer: What's the best mix of Covid-19 vaccines and boosters? Early indications and studies may shed some light - TODAY Explainer: What's the best mix of Covid-19 vaccines and boosters? Early indications and studies may shed some light - TODAY](https://onecms-res.cloudinary.com/image/upload/s--q6tjowVc--/c_fill%2Cg_auto%2Ch_676%2Cw_1200/f_auto%2Cq_auto/v1/tdy-migration/vaccines_0.jpg?itok=4VXSWjN0)
Explainer: What's the best mix of Covid-19 vaccines and boosters? Early indications and studies may shed some light - TODAY
![A mix-and-match approach to COVID-19 vaccines could provide logistical and immunological benefits | PBS NewsHour A mix-and-match approach to COVID-19 vaccines could provide logistical and immunological benefits | PBS NewsHour](https://d3i6fh83elv35t.cloudfront.net/static/2021/06/GettyImages-1232570041-768x522.jpg)
A mix-and-match approach to COVID-19 vaccines could provide logistical and immunological benefits | PBS NewsHour
![Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study | University of Oxford Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study | University of Oxford](https://www.ox.ac.uk/sites/files/oxford/field/field_image_main/Com-Cov%20news.jpg)
Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study | University of Oxford
![More frequent side-effects reported mixing Pfizer and Oxford Covid jabs, study suggests | Vaccines and immunisation | The Guardian More frequent side-effects reported mixing Pfizer and Oxford Covid jabs, study suggests | Vaccines and immunisation | The Guardian](https://i.guim.co.uk/img/media/f456ddc214eb37c55ea3719db6f557f62ff39f1d/0_31_3500_2100/master/3500.jpg?width=1200&quality=85&auto=format&fit=max&s=6a9e11cd57c195b109709d248d3abfea)
More frequent side-effects reported mixing Pfizer and Oxford Covid jabs, study suggests | Vaccines and immunisation | The Guardian
![Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK - The Lancet](https://www.thelancet.com/cms/attachment/f3be98d8-d68c-4273-a286-fc9e5079f0d6/gr1.jpg)